Drug Landscape ›
Triatec HCT 5 ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 14
Most-reported reactions
Abdominal Pain Upper — 2 reports (14.29%) Diarrhoea — 2 reports (14.29%) Drug Interaction — 2 reports (14.29%) Vomiting — 2 reports (14.29%) Acute Kidney Injury — 1 report (7.14%) Agitation — 1 report (7.14%) Anaphylactoid Reaction — 1 report (7.14%) Angioedema — 1 report (7.14%) Asthenia — 1 report (7.14%) Atrial Fibrillation — 1 report (7.14%)
Source database →
Triatec HCT 5 in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Triatec HCT 5 approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Triatec HCT 5 in United States?
Heart Care Foundation is the originator. The local marketing authorisation holder may differ — check the official source linked above.